Menu Schließen

Market Opportunity

Market Opportunity

We expect that more end-stage renal disease (ESRD) patients are going to use peritoneal dialysis (PD) for the following reasons:

  • Continued increase of chronic kidney disease (CKD) prevalence
  • Aim of healthcare systems globally to contain associated cost
  • Existing advantages of PD dialysis therapy
  • Metabolic improvement of osmotic driver agents
  • Increased biocompatibility PD fluids

More wide-spread use of PD treatment would reduce healthcare costs substantially and create enormous opportunity for Opterion.

Some governments, such as the US, have recognized the need to increase home dialysis including PD. Therefore, the number of ESRD patients on dialysis has grown dramatically in recent years and might reach almost 5 million patients worldwide by 2025, of which more than 1 million are expected to be in the US.

Despite constant healthcare reforms and reimbursement pressures, yearly US treatment costs have increased dramatically and are forecasted to exceed USD 40 billion by 2025 for example.

Accounting for around 1% of all US Medicare patients, dialysis costs consumes more than 7% of the total Medicare budget. Measures to manage costs and improve outcomes are urgently needed.

Reference: Opterion estimates based on various publications and public sources.

Massive room to expand home dialysis

Although PD offers better outcomes for many patients and is substantially cheaper than Hemodialysis (HD), only 7% of all US patients are treated with PD due to the challenges of existing reimbursement systems.

If, for example, PD penetration grew to just 14% by 2025, we estimate that the US health system could save USD 735 million a year. Similar saving potential, in combination with potentially better patient outcomes, exists in many other well-developed countries as for example Germany and France (PD usage < 10%).

HHD & PD are complementary home dialysis alternatives

Opterion assumes that in the future the US administration will force higher PD (and Home Hemodialysis, HHD) usage. By 2025, PD might account for 14% of all US patients, compared to currently 7%. This may sound high, but given that PD usage in countries like Canada, Sweden and Australia is already above 20%, and taken the enormous costs saving potential for the system in consideration, 14% is hardly ambitious.

Stefan Wohlfeil

Board Member
Stefan Wohlfeil, MD, has over 35 years of experience in the Pharma and Biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety. Prior to that he was Global Head Clinical Research & Pharmacology at Novartis and Bayer. He also has experience as founder and CEO of two start-up companies in the oncology area, one of which was based in Japan. Stefan started his career at Bayer Pharma, where he worked for over 20 years in discovery research and preclinical and clinical development in Germany, USA and Japan. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.

Andreas Schmidt

CFO / Board

Andreas Schmid has more than 25 years of experience in Finance in the Life Sciences. He worked as a Pharma Analyst at Merrill Lynch and also has experience in fund raising as well as business development.

During the span of his career Andreas was one of the highest-ranked dialysis and generic pharma analysts, with special expertise in European and CEE/emerging markets. His coverage universe included companies such as Fresenius/FMC (Germany), Gambro (Sweden), Stada (Germany) and Aspen (South Africa). Furthermore, he played a major part in the IPOs of Zentiva (Czech Republic) and Hikma (Jordan). Andreas has also been active as a speaker at various industry conferences, for example in New York, Frankfurt, but also in Warsaw and other Eastern European countries.

In addition, Andreas works as finance lecturer at the Hochschule Pforzheim and is a board member of the German shareholder association SdK.

Ricardo Cordero

Vice Chairman
Dr Ricardo Cordero, PhD, serves as Vice Chairman of Opterion Health since 2016. Ricardo has over 30 years of experience in the Financial Services Industry where he held various senior positions, for example as CEO of BZ Bank, Managing Partner at Reichmuth & Co Investmentfonds AG, Co-founder and Co-CEO at BWO Bank, etc. Further, he is a passionate and experienced private Swiss investor and holds various investments in the Life Science, Technology and high-end Consumer Goods industry.

David Ebsworth

Chairman
Dr David Ebsworth, PhD, has been Chairman of Opterion Health since December 2016. David has over 40 years of experience in the Pharma, Healthcare and Biotech industry. David is a past CEO of Galenica, Vifor Pharma as well as Oxford GlycoSciences and past global head of the Pharmaceutical Division of Bayer. He has chaired several private and public companies and has served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David is currently Chairman of Verona Pharma and Actimed Therapeutics.

Guido Grentzmann

CEO / CSO / Board
Dr Guido Grenzmann, PhD, is the founder of Opterion Health and has more than 25 years of experience in Pharma R&D and Project Management. After academic work on bacterial and viral mechanisms of translational regulation, he became Group Leader Molecular Biology/Genomics at Pfizer and Director Biochemistry/GeneProfiling at Altana Pharma where he worked in Discovery of inflammation in respiratory diseases. In 2007 he founded PBS PharmaBioServices providing contract research and consulting mainly in inflammatory diseases, in multiple therapeutic domains. 2012, Guido founded Opterion, with the aim to develop a new PD solution, to decrease side-effects of this promising therapy.